-
甲状腺相关眼病(thyroid associated ophthalmopathy,TAO)又称为Graves眼病,是一种机制不清的自身免疫疾病,与甲状腺疾病密切相关[1]。放射治疗用于激素治疗无效的患者或作为全身治疗中的局部治疗,有效率约为60%[2-4]。目前较少有人讨论TAO放射治疗的靶区及照射技术,治疗剂量及分割方式尚存争议,这些问题可能是TAO放疗有效率多年来无明显提高的主要原因。近年来随着放射治疗技术的飞速发展及相关临床证据的不断出现,对于甲状腺相关眼病的放射治疗也有了新的思考。
甲状腺相关眼病的放射治疗进展
The development of radiotherapy for thyroid associated ophthalmopathy
-
摘要: 甲状腺相关眼病是一种机制不清的自身免疫疾病,放射治疗对缓解眼部症状有一定疗效,对传统放疗技术的沿用可能是有效率无明显提高的主要原因。随着放射治疗技术的发展,靶区、剂量等更多问题值得探讨,尤其是调强放疗,相比传统放疗,它具有靶区内剂量分布均匀、靶区外剂量梯度大等特点,可能对提高有效率、保护正常组织更有帮助。Abstract: Thyroid-associated ophthalmopathy is an autoimmune disease with unclear mechanism. Radiotherapy has certain curative effect to relieve the eye symptoms. Usage of traditional radiotherapy technology might be the reason of no discernible improved efficiency. However, with the progress of radiotherapy, it is found that more problems like target volume, dose and radiotherapy which is especially stressed deserves further investigation. Compared with the traditional radiotherapy, the modern radiotherapy is featured with even dose distribution in target volume and large dose gradient outside target volume. Therefore, it is more helpful in improving efficiency and protecting normal tissue.
-
[1] 宋国祥, 吴中耀.眼眶病学[M].北京:人民卫生出版社, 1999: 212-223.
[2] Donaldson SS, Bagshaw MA, Kriss JP. Supervoltage orbital radiotherapy for Graves' ophthalmopathy[J]. J Clin Endocrinol Metab, 1973, 37(2): 276-285. doi: 10.1210/jcem-37-2-276 [3] Olivotto IA, Ludgate CM, Allen LH, et al. Supervoltage radiotherapy for Graves' ophthalmopathy: CCABC technique and results[J]. Int J RadiatOncol Biol Phys, 1985, 11(12): 2085-2090. doi: 10.1016/0360-3016(85)90088-4 [4] Prummel MF, Mourits MP, Blank L, et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves′ ophthalmopathy[J]. Lancet, 1993, 342(8877): 949-954. doi: 10.1016/0140-6736(93)92001-A [5] Harris MA, Realini T, Hogg JP, et al. CT dimensions of the lacrimal gland in Graves orbitopathy[J]. Ophthal Plast Reconstr Surg, 2012, 28(1): 69-72. [6] 黑砚, 康莉, 李月月, 等.甲状腺相关眼病眼眶组织的病理改变[J].中华眼科杂志, 2008, 44(5): 423-426.
[7] Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves′ ophthalmopathy[J]. J Clin Endocrinol Metab, 2004, 89(1): 15-20. doi: 10.1210/jc.2003-030809 [8] Mourits MP, van Kempen-Harteveld ML, García MB, et al. Radiotherapy for Graves′ orbitopathy: randomised placebo-controlled study[J]. Lancet, 2000, 355(9214): 1505-1509. doi: 10.1016/S0140-6736(00)02165-6 [9] Gripp S, Doeker R, Glag M, et al. Conventional and virtual simulation in retrobulbar irradiation[J]. Strahlenther Onkol, 2000, 176(3): 131-134. doi: 10.1007/PL00002338 [10] Katz HR, Danoff B, Kramer S. Computerized orbital tomography in the radiotherapeutic treatment planning of graves′ ophthalmopathy[J]. Int J RadiatOncol Biol Phys, 1977, 2 Suppl 2: S150. [11] Dagi LR, Zoumalan CI, Konrad H, et al. Correlation between extraocular muscle size and motility restriction in thyroid eye disease[J]. Ophthal Plast Reconstr Surg, 2011, 27(2): 102-110 [12] Nguyen NP, Krafft SP, Vos P, et al. Feasibility of tomotherapy for Graves′ ophthalmopathy: Dosimetry comparison with conventional radiotherapy[J]. Strahlenther Onkol, 2011, 187(9): 568-574. doi: 10.1007/s00066-011-2220-z [13] Espinoza S, Saboori M, Forman S, et al. Use of stereotactic intensity-modulated radiotherapy in thyroid-related ophthalmopathy. Case report[J]. J Neurosurg, 2004, 101 suppl3: S396-401 [14] Lee VH, Ng SC, Choi CW, et al. Comparative analysis of dosimetric parameters of three different radiation techniques for patients with Graves′ ophthalmopathy treated with retro-orbital irradiation[J]. Radiat Oncol, 2012, 7(1): 199. doi: 10.1186/1748-717X-7-199 [15] Wakelkamp IM, Tan H, Saeed P, et al. Orbital irradiation for Graves′ ophthalmopathy: Is it safe? A long-term follow-up study[J]. Ophthalmology, 2004, 111(8): 1557-1562. doi: 10.1016/j.ophtha.2003.12.054 [16] Matthiesen C, Thompson JS, Thompson D, et al. The efficacy of radiation therapy in the treatment of Graves′ orbitopathy[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1): 117-123. doi: 10.1016/j.ijrobp.2010.08.053 [17] Heyd R, Seegenschmiedt MH, Strassmann G, et al. Radiotherapy for Graves′ orbitopathy: results of a national survey[J]. Strahlenther Onkol, 2003, 179(6): 372-376. doi: 10.1007/s00066-003-0911-9 [18] Kahaly GJ, Rösler HP, Pitz S, et al. Low-versus high-dose radiotherapy for Graves′ ophthalmopathy: a randomized, single blind trial[J]. J Clin Endocrinol Metab, 2000, 85(1): 102-108. [19] Gerling J, Kommerell G, Henne K, et al. Retrobulbar irradiation for thyroid-associated orbitopathy: double-blind comparison between 2. 4 and 16 Gy[J]. Int J Radiat Oncol Biol Phys, 2003, 55(1): 182-189. doi: 10.1016/S0360-3016(02)03795-1
计量
- 文章访问数: 2546
- HTML全文浏览量: 1638
- PDF下载量: 5